OUT NOW: Revised ESE Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas
OUT NOW: Revised ESE Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas
The European Society of Endocrinology (ESE) has published a Revised Clinical Practice Guideline for the Management of Aggressive Pituitary Tumours (APT) and Pituitary Carcinomas (PC) in the European Journal of Endocrinology, Volume 192, Issue 6, June 2025. The Revised Guideline aims to support physicians worldwide in optimising care for patients facing these complex and rare neuroendocrine tumours.
Professor Gérald Raverot (Lyon, France), Guideline Chair, said: “It was time for a new version of the Guideline because a lot of studies have been published with new data including long-term evaluation of patients and new prognostic markers.
“Thanks to all these publications during the last six years, we are now able to propose a better definition of aggressive pituitary tumours and to suggest some prognostic markers that help physicians to identify early-on the patients with potential aggressive pituitary tumours.”
The Revised Guideline builds upon the original 2018 ESE publication and integrates the latest evidence, including findings from the second ESE survey on APT and PC. It incorporates clinical experience and new data on emerging treatment options such as immune checkpoint inhibitors, bevacizumab and expanded use of temozolomide.
A practical management algorithm has been introduced to assist clinicians in therapeutic decision-making, along with updated recommendations for standardised imaging, pathology reporting and the use of molecular diagnostics.
Importantly, the revision reflects a more collaborative and international approach, with input from a broader range of experts including endocrinologists, neurosurgeons, neuro-oncologists, pathologists and molecular biologists.
The guideline also addresses special clinical situations such as APT during pregnancy and outlines future directions for research.
Read the Guideline here.
The ESE guideline programme will publish two further Guidelines in 2025: the ESE Clinical Practice Guideline for Management and Evaluation of Menopause and the Perimenopause, and the Revised ESE Clinical Practice Guideline on the Management of Chronic Hypoparathyroidism. Find out more
Professor Raverot discusses the reason for the Revised Guideline, who it is for and key changes since the 2018 Guideline.
16/06/2025